Live Chat

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

Latest news

Frances Wang 2024 Dec 02, 16:00

Gold Price Dropped Below $2,650 as US Dollar Rises on Trump Tariff Threat

Commodities
Frances Wang 2024 Dec 02, 16:00

GBP to USD forecast: GBP/USD Records Its Best Week Since September

Forex
Frances Wang 2024 Dec 02, 16:00

Supermicro stock surged almost 30%: Why SMCI Stock Is Surging Again?

Stocks
Frances Wang 2024 Dec 02, 16:00

BTC Price Forecast and Bitcoin Technical Analysis: Will Bitcoin Reach $100K?

Cryptocurrencies
Neil Wilson 2024 Dec 02, 16:00

Week Ahead: Markets on the Move: Stocks Rally Amid Economic Uncertainty

Stocks Morning Note
Frances Wang 2024 Dec 01, 16:00

Forex market news: Japanese Yen Sharply Declines Against USD

Forex
Frances Wang 2024 Dec 01, 16:00

Solana Price Prediction: Will SOL Hit $1,000 after its impressive rebound

Cryptocurrencies
Frances Wang 2024 Dec 01, 16:00

FTSE 100 Index Today: FTSE 100 companies recognize supply chain as key risk

Indices

Info

Spread

0.12

Spread (%)

1.3001 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Tuesday

14:31 - 20:59

Monday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1096251264

Shares Outstanding

137720000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.93

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments
Trustpilot
Live Chat